Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fluorodeoxyglucose F18 | 42 | 2023 | 1982 | 4.940 |
Why?
|
Radiopharmaceuticals | 37 | 2022 | 2643 | 2.310 |
Why?
|
Inflammatory Breast Neoplasms | 9 | 2021 | 122 | 2.280 |
Why?
|
Positron-Emission Tomography | 47 | 2023 | 6180 | 2.010 |
Why?
|
Organometallic Compounds | 4 | 2022 | 657 | 1.420 |
Why?
|
Neuroendocrine Tumors | 5 | 2023 | 577 | 1.380 |
Why?
|
Radium | 5 | 2020 | 54 | 1.310 |
Why?
|
Lutetium | 3 | 2023 | 30 | 1.190 |
Why?
|
Dipeptides | 4 | 2023 | 411 | 1.180 |
Why?
|
Heterocyclic Compounds, 1-Ring | 3 | 2023 | 64 | 1.150 |
Why?
|
Octreotide | 4 | 2022 | 144 | 1.150 |
Why?
|
Adipose Tissue, Brown | 4 | 2021 | 764 | 1.090 |
Why?
|
Nuclear Medicine | 6 | 2023 | 224 | 1.080 |
Why?
|
Tomography, X-Ray Computed | 28 | 2020 | 19903 | 1.050 |
Why?
|
Radioimmunotherapy | 7 | 2013 | 76 | 1.030 |
Why?
|
Lymphoma | 7 | 2017 | 1859 | 1.020 |
Why?
|
Hodgkin Disease | 4 | 2022 | 1410 | 1.010 |
Why?
|
Dihydrotestosterone | 2 | 2023 | 192 | 1.000 |
Why?
|
Bone Neoplasms | 6 | 2020 | 2512 | 1.000 |
Why?
|
Prostate-Specific Antigen | 5 | 2023 | 2352 | 0.830 |
Why?
|
Receptors, Peptide | 2 | 2022 | 274 | 0.790 |
Why?
|
Cyclobutanes | 1 | 2020 | 59 | 0.720 |
Why?
|
Ribs | 1 | 2021 | 230 | 0.720 |
Why?
|
Mouth Neoplasms | 2 | 2022 | 578 | 0.720 |
Why?
|
Carboxylic Acids | 1 | 2020 | 98 | 0.710 |
Why?
|
Hematologic Neoplasms | 2 | 2021 | 1726 | 0.660 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2023 | 1320 | 0.590 |
Why?
|
Diagnostic Imaging | 5 | 2017 | 3461 | 0.570 |
Why?
|
Radionuclide Imaging | 8 | 2023 | 2017 | 0.540 |
Why?
|
Carcinoma, Lobular | 1 | 2020 | 484 | 0.540 |
Why?
|
Radioisotopes | 6 | 2023 | 502 | 0.510 |
Why?
|
Molecular Imaging | 2 | 2012 | 830 | 0.500 |
Why?
|
Patient Care Planning | 1 | 2020 | 926 | 0.500 |
Why?
|
Radiometry | 6 | 2023 | 800 | 0.490 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2023 | 8896 | 0.490 |
Why?
|
Breast Neoplasms | 8 | 2023 | 20448 | 0.470 |
Why?
|
Stem Cell Transplantation | 3 | 2023 | 1631 | 0.470 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1096 | 0.430 |
Why?
|
Radiotherapy | 3 | 2018 | 1536 | 0.430 |
Why?
|
Blood Glucose | 3 | 2018 | 6212 | 0.420 |
Why?
|
Neoplasm Metastasis | 4 | 2020 | 4887 | 0.410 |
Why?
|
Parathyroid Neoplasms | 2 | 2010 | 243 | 0.410 |
Why?
|
Humans | 106 | 2023 | 725001 | 0.390 |
Why?
|
Colon | 1 | 2019 | 1770 | 0.390 |
Why?
|
Head and Neck Neoplasms | 3 | 2022 | 2671 | 0.380 |
Why?
|
Carcinoma | 5 | 2021 | 2337 | 0.380 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5217 | 0.350 |
Why?
|
Antibodies, Monoclonal | 6 | 2017 | 9248 | 0.350 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 3 | 2009 | 1114 | 0.350 |
Why?
|
Prostatic Neoplasms | 4 | 2023 | 10879 | 0.340 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2022 | 3948 | 0.340 |
Why?
|
Genital Neoplasms, Female | 1 | 2014 | 508 | 0.330 |
Why?
|
Transplantation, Autologous | 4 | 2023 | 2072 | 0.320 |
Why?
|
Endometrial Neoplasms | 1 | 2017 | 1330 | 0.320 |
Why?
|
Hyperparathyroidism | 1 | 2008 | 338 | 0.300 |
Why?
|
Neck Muscles | 1 | 2007 | 104 | 0.300 |
Why?
|
Retrospective Studies | 29 | 2022 | 74145 | 0.300 |
Why?
|
Neoplasms | 11 | 2018 | 20947 | 0.300 |
Why?
|
Neoplasm Staging | 9 | 2021 | 10926 | 0.300 |
Why?
|
Immunotherapy | 3 | 2022 | 4257 | 0.300 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 4119 | 0.290 |
Why?
|
Diagnosis, Differential | 9 | 2020 | 12937 | 0.290 |
Why?
|
Intercostal Muscles | 1 | 2004 | 26 | 0.260 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2020 | 11303 | 0.260 |
Why?
|
Lymphatic Diseases | 1 | 2006 | 321 | 0.250 |
Why?
|
Adult | 39 | 2022 | 211523 | 0.250 |
Why?
|
Tissue Distribution | 5 | 2019 | 2360 | 0.240 |
Why?
|
Female | 52 | 2023 | 375303 | 0.240 |
Why?
|
Middle Aged | 45 | 2021 | 212155 | 0.240 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2006 | 638 | 0.230 |
Why?
|
Treatment Outcome | 19 | 2022 | 61674 | 0.230 |
Why?
|
Male | 46 | 2023 | 346964 | 0.230 |
Why?
|
Neck | 1 | 2007 | 686 | 0.230 |
Why?
|
Aged | 39 | 2022 | 161379 | 0.230 |
Why?
|
Adenoma | 2 | 2010 | 2166 | 0.210 |
Why?
|
Head | 1 | 2007 | 855 | 0.210 |
Why?
|
Lymphatic Metastasis | 3 | 2021 | 2901 | 0.210 |
Why?
|
Receptors, Somatostatin | 2 | 2023 | 129 | 0.210 |
Why?
|
Adrenocortical Carcinoma | 1 | 2022 | 85 | 0.210 |
Why?
|
Subtraction Technique | 1 | 2004 | 526 | 0.200 |
Why?
|
Taxoids | 2 | 2022 | 660 | 0.200 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2017 | 1761 | 0.200 |
Why?
|
Lymphoma, B-Cell | 1 | 2007 | 929 | 0.200 |
Why?
|
Paraganglioma | 1 | 2022 | 145 | 0.190 |
Why?
|
Prognosis | 7 | 2022 | 28718 | 0.190 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2022 | 160 | 0.190 |
Why?
|
Radiotherapy Dosage | 6 | 2021 | 2885 | 0.190 |
Why?
|
Gastric Emptying | 1 | 2022 | 238 | 0.190 |
Why?
|
Mastectomy | 4 | 2021 | 1752 | 0.190 |
Why?
|
Receptors, Progesterone | 3 | 2020 | 1096 | 0.180 |
Why?
|
Pheochromocytoma | 1 | 2022 | 339 | 0.180 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 615 | 0.180 |
Why?
|
Education, Medical | 1 | 2012 | 1700 | 0.180 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2018 | 1604 | 0.180 |
Why?
|
Internship and Residency | 3 | 2022 | 5690 | 0.180 |
Why?
|
Cholecystokinin | 1 | 2019 | 116 | 0.170 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2019 | 138 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2018 | 3449 | 0.170 |
Why?
|
Thyroid Neoplasms | 2 | 2009 | 2227 | 0.170 |
Why?
|
Survival Analysis | 4 | 2021 | 10244 | 0.170 |
Why?
|
Body Weight | 1 | 2009 | 4657 | 0.160 |
Why?
|
Neoplasm, Residual | 5 | 2023 | 965 | 0.160 |
Why?
|
Gallbladder | 1 | 2019 | 305 | 0.160 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2020 | 215 | 0.160 |
Why?
|
Aged, 80 and over | 20 | 2020 | 57615 | 0.160 |
Why?
|
Neoadjuvant Therapy | 5 | 2023 | 2618 | 0.160 |
Why?
|
Parathyroid Glands | 2 | 2010 | 509 | 0.160 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2017 | 880 | 0.150 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2017 | 979 | 0.150 |
Why?
|
Receptors, Androgen | 1 | 2023 | 1035 | 0.150 |
Why?
|
Crohn Disease | 1 | 2009 | 2258 | 0.150 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2022 | 737 | 0.150 |
Why?
|
Receptor, erbB-2 | 4 | 2020 | 2334 | 0.150 |
Why?
|
Whole-Body Irradiation | 1 | 2017 | 450 | 0.140 |
Why?
|
Axilla | 1 | 2018 | 574 | 0.140 |
Why?
|
Uveal Neoplasms | 1 | 2018 | 304 | 0.140 |
Why?
|
Hepatitis C | 1 | 2006 | 1565 | 0.140 |
Why?
|
Oncology Service, Hospital | 1 | 2016 | 56 | 0.140 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 437 | 0.140 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 13563 | 0.140 |
Why?
|
Intestinal Neoplasms | 2 | 2018 | 319 | 0.130 |
Why?
|
Beta Particles | 1 | 2015 | 50 | 0.130 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2012 | 1384 | 0.130 |
Why?
|
Artifacts | 2 | 2018 | 1888 | 0.130 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2009 | 686 | 0.130 |
Why?
|
Receptors, Estrogen | 2 | 2020 | 2167 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 794 | 0.120 |
Why?
|
Remission Induction | 2 | 2017 | 2366 | 0.120 |
Why?
|
Sensitivity and Specificity | 7 | 2010 | 14713 | 0.120 |
Why?
|
Prostate | 1 | 2022 | 1679 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 9589 | 0.120 |
Why?
|
Genes, Retinoblastoma | 1 | 2014 | 138 | 0.120 |
Why?
|
Glucose | 2 | 2022 | 4315 | 0.110 |
Why?
|
Triazoles | 1 | 2018 | 909 | 0.110 |
Why?
|
Combined Modality Therapy | 6 | 2021 | 8577 | 0.110 |
Why?
|
Lymphoma, Follicular | 2 | 2013 | 424 | 0.110 |
Why?
|
Lymph Node Excision | 1 | 2018 | 1220 | 0.110 |
Why?
|
Vascular Neoplasms | 1 | 2014 | 177 | 0.110 |
Why?
|
Radiology Department, Hospital | 1 | 2016 | 407 | 0.100 |
Why?
|
Ultrasonography, Mammary | 1 | 2013 | 247 | 0.100 |
Why?
|
Follow-Up Studies | 4 | 2020 | 38720 | 0.100 |
Why?
|
Sirolimus | 2 | 2009 | 1551 | 0.100 |
Why?
|
Radiation Dosage | 2 | 2017 | 1917 | 0.100 |
Why?
|
Vena Cava, Inferior | 1 | 2014 | 433 | 0.100 |
Why?
|
Bone Marrow | 3 | 2010 | 2909 | 0.100 |
Why?
|
Vaccination | 1 | 2022 | 3121 | 0.090 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2014 | 606 | 0.090 |
Why?
|
Leiomyosarcoma | 1 | 2014 | 457 | 0.090 |
Why?
|
Epithelial Cells | 1 | 2022 | 3638 | 0.090 |
Why?
|
Bone Marrow Neoplasms | 1 | 2010 | 106 | 0.090 |
Why?
|
Mammaplasty | 1 | 2019 | 1155 | 0.090 |
Why?
|
Cold Temperature | 2 | 2010 | 780 | 0.090 |
Why?
|
Oxygen Radioisotopes | 1 | 2008 | 77 | 0.090 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 287 | 0.080 |
Why?
|
Fibrous Dysplasia of Bone | 1 | 2008 | 47 | 0.080 |
Why?
|
Rats, Inbred Lew | 2 | 2010 | 1151 | 0.080 |
Why?
|
Ovarian Neoplasms | 2 | 2021 | 4755 | 0.080 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2008 | 177 | 0.080 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2010 | 149 | 0.080 |
Why?
|
Bronchial Neoplasms | 1 | 2008 | 115 | 0.080 |
Why?
|
Intestinal Mucosa | 1 | 2019 | 3031 | 0.080 |
Why?
|
Molecular Mimicry | 1 | 2008 | 199 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2284 | 0.080 |
Why?
|
Parathyroidectomy | 1 | 2010 | 234 | 0.080 |
Why?
|
Benzamides | 1 | 2013 | 1372 | 0.080 |
Why?
|
Hypertrophy | 1 | 2009 | 566 | 0.080 |
Why?
|
Smoking | 1 | 2004 | 8882 | 0.080 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 946 | 0.080 |
Why?
|
Hematopoiesis, Extramedullary | 1 | 2007 | 63 | 0.080 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2013 | 647 | 0.080 |
Why?
|
Survival Rate | 5 | 2017 | 12795 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 7256 | 0.070 |
Why?
|
Immunologic Factors | 1 | 2016 | 1544 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3478 | 0.070 |
Why?
|
Hematologic Diseases | 1 | 2010 | 492 | 0.070 |
Why?
|
Longitudinal Studies | 1 | 2023 | 13692 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5480 | 0.070 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2007 | 425 | 0.070 |
Why?
|
Disease-Free Survival | 5 | 2017 | 6881 | 0.070 |
Why?
|
Population Surveillance | 1 | 2017 | 2645 | 0.070 |
Why?
|
Filgrastim | 1 | 2006 | 131 | 0.070 |
Why?
|
Mastectomy, Modified Radical | 2 | 2017 | 65 | 0.070 |
Why?
|
Radiation Injuries | 1 | 2013 | 1165 | 0.070 |
Why?
|
Risk | 1 | 2018 | 9697 | 0.070 |
Why?
|
Constriction, Pathologic | 1 | 2009 | 1055 | 0.070 |
Why?
|
Metabolic Clearance Rate | 1 | 2006 | 394 | 0.070 |
Why?
|
Hormones | 2 | 2022 | 868 | 0.070 |
Why?
|
Pyrimidines | 2 | 2018 | 2895 | 0.070 |
Why?
|
Contrast Media | 1 | 2019 | 5244 | 0.070 |
Why?
|
Laboratories | 1 | 2009 | 455 | 0.070 |
Why?
|
Thyrotropin | 1 | 2009 | 817 | 0.070 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2009 | 317 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2741 | 0.070 |
Why?
|
Arteries | 1 | 2010 | 1107 | 0.060 |
Why?
|
Drug Evaluation | 1 | 2006 | 649 | 0.060 |
Why?
|
Muscles | 1 | 2009 | 1603 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 6527 | 0.060 |
Why?
|
Young Adult | 6 | 2017 | 55791 | 0.060 |
Why?
|
Skull | 1 | 2008 | 800 | 0.060 |
Why?
|
Leukemia | 1 | 2012 | 1495 | 0.060 |
Why?
|
Bleomycin | 2 | 2017 | 510 | 0.060 |
Why?
|
Time Factors | 5 | 2019 | 40178 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12244 | 0.060 |
Why?
|
Thrombocytopenia | 2 | 2010 | 1160 | 0.060 |
Why?
|
Vinblastine | 2 | 2017 | 499 | 0.060 |
Why?
|
Hernia, Inguinal | 1 | 2005 | 200 | 0.060 |
Why?
|
Doxorubicin | 3 | 2017 | 2224 | 0.060 |
Why?
|
Observer Variation | 1 | 2009 | 2608 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2018 | 3022 | 0.060 |
Why?
|
Pelvic Neoplasms | 1 | 2005 | 254 | 0.060 |
Why?
|
Piperazines | 1 | 2013 | 2482 | 0.060 |
Why?
|
Edetic Acid | 1 | 2023 | 281 | 0.060 |
Why?
|
Mammography | 1 | 2013 | 2442 | 0.050 |
Why?
|
Kinetics | 3 | 2021 | 6554 | 0.050 |
Why?
|
Aromatase Inhibitors | 1 | 2006 | 493 | 0.050 |
Why?
|
Gallium Radioisotopes | 1 | 2023 | 166 | 0.050 |
Why?
|
Toes | 1 | 2023 | 203 | 0.050 |
Why?
|
Patient Care Team | 1 | 2013 | 2541 | 0.050 |
Why?
|
Drug Administration Schedule | 3 | 2017 | 4939 | 0.050 |
Why?
|
Dacarbazine | 2 | 2017 | 565 | 0.050 |
Why?
|
Protein Kinases | 1 | 2009 | 1634 | 0.050 |
Why?
|
Surgery, Computer-Assisted | 1 | 2010 | 1006 | 0.050 |
Why?
|
Succinate Dehydrogenase | 1 | 2022 | 154 | 0.050 |
Why?
|
Thoracic Vertebrae | 1 | 2006 | 605 | 0.050 |
Why?
|
Tamoxifen | 1 | 2006 | 985 | 0.050 |
Why?
|
Organ Specificity | 1 | 2006 | 2022 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 2 | 2023 | 1803 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2006 | 1367 | 0.050 |
Why?
|
Phantoms, Imaging | 1 | 2009 | 2471 | 0.050 |
Why?
|
Polyethylene Glycols | 1 | 2006 | 1179 | 0.050 |
Why?
|
Melanoma | 1 | 2018 | 5357 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2009 | 2512 | 0.050 |
Why?
|
Adenocarcinoma | 2 | 2008 | 6351 | 0.050 |
Why?
|
Abdomen | 1 | 2006 | 1101 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 6 | 2021 | 34755 | 0.050 |
Why?
|
Technetium Tc 99m Lidofenin | 1 | 2019 | 3 | 0.050 |
Why?
|
Spleen | 1 | 2006 | 2376 | 0.050 |
Why?
|
Recombinant Proteins | 2 | 2009 | 6669 | 0.050 |
Why?
|
Risk Factors | 3 | 2018 | 70971 | 0.050 |
Why?
|
Forecasting | 1 | 2009 | 2933 | 0.050 |
Why?
|
Societies, Medical | 1 | 2012 | 3706 | 0.040 |
Why?
|
Monte Carlo Method | 3 | 2010 | 1297 | 0.040 |
Why?
|
Radioactive Tracers | 1 | 2019 | 75 | 0.040 |
Why?
|
Spinal Neoplasms | 1 | 2006 | 757 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2017 | 2259 | 0.040 |
Why?
|
Cyclophosphamide | 2 | 2017 | 2205 | 0.040 |
Why?
|
United States | 3 | 2023 | 68433 | 0.040 |
Why?
|
Reoperation | 1 | 2008 | 4156 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12318 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 7835 | 0.040 |
Why?
|
Prospective Studies | 1 | 2023 | 51853 | 0.040 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 699 | 0.040 |
Why?
|
Reference Values | 1 | 2006 | 4997 | 0.040 |
Why?
|
Consent Forms | 1 | 2018 | 51 | 0.040 |
Why?
|
Rectal Neoplasms | 1 | 2007 | 1141 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2009 | 19620 | 0.040 |
Why?
|
Cytarabine | 1 | 2020 | 683 | 0.040 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2006 | 1512 | 0.040 |
Why?
|
Disease Progression | 4 | 2016 | 13161 | 0.040 |
Why?
|
Treatment Failure | 2 | 2015 | 2613 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2010 | 892 | 0.040 |
Why?
|
Oligopeptides | 1 | 2023 | 1200 | 0.040 |
Why?
|
Pilot Projects | 2 | 2009 | 8099 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2015 | 8644 | 0.040 |
Why?
|
Recurrence | 1 | 2008 | 8216 | 0.040 |
Why?
|
Indazoles | 1 | 2018 | 287 | 0.040 |
Why?
|
Tissue Extracts | 1 | 2016 | 142 | 0.040 |
Why?
|
Career Choice | 1 | 2022 | 742 | 0.030 |
Why?
|
Acute Disease | 1 | 2006 | 7090 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2007 | 2539 | 0.030 |
Why?
|
Patient Selection | 2 | 2023 | 4196 | 0.030 |
Why?
|
Eating | 1 | 2022 | 1524 | 0.030 |
Why?
|
Anthracyclines | 1 | 2017 | 274 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 2010 | 4171 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 130 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2008 | 3345 | 0.030 |
Why?
|
Cohort Studies | 1 | 2017 | 39883 | 0.030 |
Why?
|
Bone Remodeling | 1 | 2018 | 577 | 0.030 |
Why?
|
Nausea | 1 | 2017 | 640 | 0.030 |
Why?
|
Rats | 2 | 2010 | 24422 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2017 | 968 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2006 | 4109 | 0.030 |
Why?
|
Radiology | 1 | 2007 | 2019 | 0.030 |
Why?
|
Biological Transport | 1 | 2017 | 2116 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 586 | 0.030 |
Why?
|
Animals | 4 | 2015 | 168735 | 0.030 |
Why?
|
Body Mass Index | 1 | 2009 | 12527 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10968 | 0.030 |
Why?
|
Radiography | 1 | 2022 | 6949 | 0.030 |
Why?
|
Models, Biological | 1 | 2008 | 9667 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2009 | 5522 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2010 | 6672 | 0.020 |
Why?
|
Estrogen Receptor alpha | 1 | 2015 | 582 | 0.020 |
Why?
|
Urinary Tract | 1 | 2013 | 289 | 0.020 |
Why?
|
B-Lymphocyte Subsets | 1 | 2012 | 252 | 0.020 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2012 | 164 | 0.020 |
Why?
|
Yttrium Radioisotopes | 1 | 2010 | 95 | 0.020 |
Why?
|
Vincristine | 1 | 2012 | 1049 | 0.020 |
Why?
|
Inflammation | 1 | 2009 | 10337 | 0.020 |
Why?
|
Predictive Value of Tests | 3 | 2010 | 14955 | 0.020 |
Why?
|
Pharyngeal Neoplasms | 1 | 2009 | 115 | 0.020 |
Why?
|
Necrosis | 1 | 2013 | 1624 | 0.020 |
Why?
|
Tonsillar Neoplasms | 1 | 2009 | 51 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6725 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2010 | 413 | 0.020 |
Why?
|
Absorption | 1 | 2009 | 253 | 0.020 |
Why?
|
Leucovorin | 1 | 2010 | 623 | 0.020 |
Why?
|
Stomach Neoplasms | 1 | 2018 | 1309 | 0.020 |
Why?
|
Sulfonamides | 1 | 2018 | 1883 | 0.020 |
Why?
|
Glucose Transporter Type 1 | 1 | 2009 | 192 | 0.020 |
Why?
|
Adolescent | 4 | 2012 | 84411 | 0.020 |
Why?
|
Clone Cells | 1 | 2012 | 1697 | 0.020 |
Why?
|
Tongue Neoplasms | 1 | 2009 | 177 | 0.020 |
Why?
|
Platelet Count | 1 | 2010 | 785 | 0.020 |
Why?
|
Gastrointestinal Tract | 1 | 2013 | 803 | 0.020 |
Why?
|
Prednisone | 1 | 2012 | 1551 | 0.020 |
Why?
|
Research Design | 1 | 2023 | 5932 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 879 | 0.020 |
Why?
|
Fluorine Radioisotopes | 1 | 2010 | 446 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2010 | 1614 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2017 | 8909 | 0.020 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2012 | 561 | 0.020 |
Why?
|
Pedigree | 1 | 2014 | 4630 | 0.020 |
Why?
|
Herpesvirus 4, Human | 1 | 2012 | 1247 | 0.020 |
Why?
|
Fluorouracil | 1 | 2010 | 1626 | 0.020 |
Why?
|
Pulmonary Alveoli | 1 | 2008 | 706 | 0.020 |
Why?
|
Methotrexate | 1 | 2012 | 1707 | 0.020 |
Why?
|
Spinal Cord | 1 | 2013 | 1810 | 0.020 |
Why?
|
Fatigue | 1 | 2012 | 1488 | 0.020 |
Why?
|
Models, Statistical | 2 | 2010 | 5081 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2008 | 1405 | 0.020 |
Why?
|
Thorax | 1 | 2007 | 533 | 0.020 |
Why?
|
Quinazolines | 1 | 2010 | 1365 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1151 | 0.010 |
Why?
|
Internationality | 1 | 2009 | 994 | 0.010 |
Why?
|
Thyroidectomy | 1 | 2009 | 877 | 0.010 |
Why?
|
World Health Organization | 1 | 2009 | 1302 | 0.010 |
Why?
|
Bone and Bones | 1 | 2013 | 2564 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9287 | 0.010 |
Why?
|
Water | 1 | 2008 | 1343 | 0.010 |
Why?
|
Mice, Nude | 1 | 2009 | 3716 | 0.010 |
Why?
|
Lung Diseases | 1 | 2012 | 1905 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2009 | 3575 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2010 | 1967 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5097 | 0.010 |
Why?
|
Temporal Lobe | 1 | 2008 | 1656 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2004 | 12874 | 0.010 |
Why?
|
Linear Models | 1 | 2010 | 5934 | 0.010 |
Why?
|
Biomedical Research | 1 | 2016 | 3281 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11486 | 0.010 |
Why?
|
Child | 1 | 2007 | 75163 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2009 | 2111 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2005 | 1447 | 0.010 |
Why?
|
Preoperative Care | 1 | 2007 | 2265 | 0.010 |
Why?
|
Neutrophils | 1 | 2010 | 3729 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2016 | 5066 | 0.010 |
Why?
|
Phosphorylation | 1 | 2009 | 8492 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 29645 | 0.010 |
Why?
|
Data Collection | 1 | 2007 | 3321 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2010 | 5169 | 0.010 |
Why?
|
Software | 1 | 2010 | 4404 | 0.010 |
Why?
|
Quality of Life | 1 | 2016 | 12113 | 0.010 |
Why?
|
Lung | 1 | 2013 | 9812 | 0.010 |
Why?
|
Computer Simulation | 1 | 2008 | 6158 | 0.010 |
Why?
|
Genetic Variation | 1 | 2009 | 6529 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2009 | 10472 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2009 | 16634 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 13759 | 0.010 |
Why?
|
Brain | 1 | 2013 | 25743 | 0.000 |
Why?
|
Mice | 1 | 2009 | 80318 | 0.000 |
Why?
|